Rapport Therapeutics Conference Call Summary Company Overview - **Company**: Rapport Therapeutics (NasdaqGM:RAPP) - **Focus**: Development of a novel drug for epilepsy treatment, specifically RAP-219, which is advancing from phase 2 to phase 3 trials [1][2] Core Points and Arguments Drug Mechanism and Efficacy - **Target**: RAP-219 is a TARP gamma-8 AMPA modulator, focusing on four brain structures to treat focal onset seizures and bipolar mania [3] - **Efficacy**: Preclinical models showed unprecedented efficacy in controlling seizures without significant adverse effects, unlike existing pan-AMPA antagonists [5][11] - **Clinical Data**: Phase 2 trial demonstrated a 78% median reduction in clinical seizures and a 72% reduction in electrographic seizures, surpassing initial expectations of 50% and 30% respectively [19][31] Safety Profile - **Tolerability**: The drug exhibited a low discontinuation rate of 10%, with all adverse events being mild to moderate, and no serious adverse events reported [21] - **Therapeutic Index**: The drug maintains a wide therapeutic index, which is crucial for its safety and efficacy [13] Trial Design and Execution - **Phase 3 Trial**: The design will include two parallel studies with approximately 330 subjects each, focusing on low-medium and mid-high dose strategies [24][25] - **Global Collaboration**: A partnership with Tenacia in China aims to enhance global development and patient enrollment for the phase 3 trials [27] Market Opportunity - **Target Population**: 30%-40% of the 1.8 million patients with focal onset seizures are refractory to current treatments, representing a significant market opportunity [30] - **Market Size**: The potential market for branded drugs in this segment is estimated at $15 billion [31] Additional Indications - **Bipolar Mania**: The drug is also being studied for bipolar mania, leveraging its mechanism to reduce glutamate transmission, which is implicated in the disorder [36][37] - **Tonic-Clonic Seizures**: Plans to initiate a phase 2 study for tonic-clonic seizures based on positive results from focal onset studies [39] Long-Acting Injectable Development - **Differentiation**: RAP-219 is being developed as a long-acting injectable (LAI), which is uncommon for anti-seizure medications. Its potency, low solubility, and long half-life make it suitable for this formulation [42][44] - **Market Impact**: The LAI could extend exclusivity and revenue durability, appealing to both patients and physicians [47] Conclusion - Rapport Therapeutics is positioned to make significant advancements in the treatment of epilepsy and bipolar disorder with its innovative drug RAP-219, backed by strong clinical data and a clear market strategy. The ongoing development of a long-acting injectable formulation further enhances its potential impact in the market [50]

Core Insights - The partnership between Rapport Therapeutics and Tenacia Biotechnology aims to leverage Tenacia's expertise in CNS drug development to accelerate the global development of RAP-219, a potential first-in-class therapy for neurological disorders [1][4] Financial Terms - Rapport will receive an upfront cash payment of $20 million, with potential additional payments of up to $308 million in development and commercialization milestones, along with tiered royalties on net sales in Greater China [3][4] Product Development - RAP-219 is being developed for multiple indications, including focal onset seizures and bipolar mania, and has shown promising results in a Phase 2a trial, demonstrating significant reductions in seizure episodes [2][6] - Two global registrational trials for RAP-219 will be conducted, with a Phase 3 program expected to start in Q2 2026, expanding its clinical trial sites in China under Tenacia's leadership [2][3] Company Profiles - Rapport Therapeutics focuses on developing small molecule precision medicines for neurological and psychiatric disorders, with a strong emphasis on epilepsy and bipolar disorder [7] - Tenacia Biotechnology, founded in 2022, aims to develop innovative therapeutics for underserved neurological disorders and is backed by Bain Capital, enhancing its capabilities in drug development [8]

Rapport Therapeutics FY Conference Summary Company Overview - **Company**: Rapport Therapeutics (NasdaqGM:RAPP) - **Industry**: Biotechnology, specifically focusing on neuroscience and epilepsy treatments Key Highlights from 2025 and Early 2026 - 2025 was a transformational year for Rapport, showcasing confirmatory data for their approach in precision neuroscience, particularly with their lead program RAP-219 targeting focal-onset seizures [3][4] - Proof-of-concept data released in September 2025 demonstrated a **72% reduction** in a novel biomarker and a **78% reduction** in clinical seizures in a refractory patient population [4][5] - A **24% seizure freedom rate** was also reported, allowing progression into registrational studies [5] Upcoming Clinical Trials - Phase 3 program for RAP-219 will be initiated in Q2 2026, accelerated from Q3 due to positive FDA interactions [5] - Two pivotal trials will be conducted in parallel, focusing on refractory focal-onset seizure patients, with three dose levels: low (0.25 mg), mid (0.75 mg), and high (1.25 mg) [6][7] Patient Population Insights - The proof-of-concept study enrolled patients with an RNS device, showing demographic similarities to those in traditional studies, but with a higher refractory rate [8][9] - 70% of enrolled patients were on 3-4 medications, indicating a highly refractory population [9] Efficacy and Safety Expectations - A clinically meaningful placebo-adjusted seizure reduction target is set at **30%-35%**, with a non-placebo adjusted target of **50%-55%** [10] - Emphasis on tolerability and ease of administration is crucial for market adoption, with a preference for once-daily dosing and minimal drug-drug interactions [11][12] Tolerability Profile - The phase 2 study reported only mild to moderate adverse events (AEs), with no severe AEs observed [14] - Anxiety was noted in some patients, but it was attributed to preexisting conditions rather than the drug itself [15][16] Market Opportunity - The market opportunity for RAP-219 in focal-onset seizures is estimated at **$2.5 billion**, based on a refractory population of 30%-40% of 1.8 million patients [18] - A long-acting injectable formulation is also in development, which could further enhance market potential [19] Long-Acting Injectable Insights - KOLs believe a long-acting injectable would be transformational for patients, addressing concerns about missed doses leading to breakthrough seizures [20][21] - The development of RAP-219 as a long-acting injectable is supported by its extended half-life and low solubility, making it suitable for this formulation [22][23] Enrollment and Trial Dynamics - Current trends show varying enrollment timelines for pivotal studies, with some taking 2-4 years [25] - Rapport aims to leverage excitement in the community and the completion of other ongoing trials to facilitate patient recruitment [26][27] Bipolar Mania Program - RAP-219 is also being explored for bipolar mania, with a focus on its potential to reduce excessive glutamate associated with the condition [28][29] - The primary endpoint for the bipolar mania trial is the Young Mania Rating Scale (YMRS), with a meaningful effect defined as a **4-point placebo-adjusted change** [35] Pain Program Focus - The company has shifted focus to a nicotinic acetylcholine receptor program for pain, which has shown promise in preclinical models [37][38] Financial Outlook - Rapport is funded into the second half of 2029, allowing for the completion of the phase 3 trial in focal-onset seizures and the phase 2 trial in bipolar mania [39] Strategic Positioning - The company is positioned to execute its programs independently, with no immediate plans for partnerships, although it remains open to opportunities that do not compromise its initiatives [42][43][44]

Core Insights - Praxis Precision Medicines has submitted two New Drug Applications (NDAs) for ulixacaltamide and relutrigine, targeting essential tremor and developmental and epileptic encephalopathies respectively, with pre-launch activities expected to accelerate through 2026 [1][3][4] - The company reported a significant increase in cash and investments, totaling $926 million as of December 31, 2025, and net proceeds of $621 million from a public offering in January 2026, which will fund operations into 2028 [10][11] Company Updates - The CEO highlighted a successful fourth quarter with multiple clinical and regulatory advancements, positioning the company for a transition into a commercial entity pending positive reviews of the NDAs [3] - Praxis is scaling its commercial organization and preparing for the launch of ulixacaltamide and relutrigine, including building inventory and initiating disease awareness campaigns [6][10] Financial Performance - As of December 31, 2025, Praxis reported cash, cash equivalents, and marketable securities of $926.1 million, a substantial increase from $469.5 million in 2024, primarily due to proceeds from a public offering [10] - Research and development expenses for Q4 2025 were $77.5 million, up from $56.3 million in Q4 2024, with total R&D expenses for the year reaching $267.1 million compared to $152.4 million in 2024 [11][12] - The company incurred a net loss of $88.9 million for Q4 2025, compared to a loss of $58.7 million in Q4 2024, and a total net loss of $303.3 million for the year [14][29] Product Development - Ulixacaltamide is the first investigational therapy to show positive results in a Phase 3 program for essential tremor, with Breakthrough Therapy Designation granted by the FDA [4][17] - Relutrigine has been granted Breakthrough Therapy Designation and Orphan Drug Designation by the FDA, targeting sodium channel modulation for developmental epileptic encephalopathies [5][19] - Vormatrigine, another product in development, is positioned as a best-in-class therapy for focal onset seizures and generalized epilepsy, with topline results expected in 2026 [8][11] Upcoming Milestones - Praxis plans to present results from the Essential3 program at the American Academy of Neurology Annual Meeting in April 2026, which will further support the launch of ulixacaltamide [4][6] - The EMERALD study for relutrigine is progressing well, with full enrollment expected in the second half of 2026, potentially leading to a supplemental NDA submission in 2027 [6][10]

Rapport Therapeutics Conference Call Summary Company Overview - Rapport Therapeutics is focused on precision neuroscience, leveraging receptor-associated proteins to enhance treatment efficacy and tolerability for patients [2][3] Key Programs - The lead program, RAP-219, is a TARP gamma-8 AMPA modulator, showing promising results in epilepsy and ongoing programs in bipolar mania [2][3] - RAP-219 has demonstrated a 78% median reduction in clinical seizure frequency and a 24% seizure freedom rate in a proof of concept study [11][12] FDA Engagement and Study Plans - The company plans to meet with the FDA by the end of 2025 for an end of phase two meeting, aiming to start phase three studies by Q3 2026 [4][5] - Two parallel registrational studies are planned, following a standard protocol for focal epilepsy [4][5] Safety and Efficacy Insights - The biological thesis focuses on modulating the AMPA receptor through TARP gamma-8, which is expressed in key brain structures related to focal seizures [6][8] - The tolerability profile from phase two data showed a 10% discontinuation rate, indicating best-in-class tolerability for anti-seizure medications [9] - Concerns regarding adverse events (AEs) related to psychiatric disorders were addressed, with no significant findings in their trials [10] Patient Population and Efficacy Expectations - The proof of concept study involved a highly refractory patient population, with 70% on three or four anti-seizure medications [16] - The efficacy results are expected to translate well into the broader phase three patient population, despite potential variability [18][13] Bipolar Mania and Other Indications - The company is exploring RAP-219 for bipolar mania, supported by the drug's mechanism targeting excitatory processes in the limbic structure [24][26] - Enrollment for the bipolar trial is progressing well, with data expected in 2027 [26] Market Opportunity - The potential market opportunity for RAP-219 in epilepsy is estimated to be multi-billion dollars, with expected utilization similar to existing treatments like Keppra [29] Upcoming Milestones - Key updates expected include the end of phase two meeting with the FDA, additional data analyses at AES in December 2025, and the initiation of phase three studies in 2026 [30][31] - The company has sufficient cash reserves, approximately $500 million, to fund operations through 2029 [32]

Core Insights - Rapport Therapeutics reported positive Phase 2a results for RAP-219, indicating a potential best-in-class profile for treating drug-resistant focal onset seizures with a nearly 78% median reduction in clinical seizures and seizure freedom in nearly 24% of patients [2][5] - The company has a strong financial position with approximately $269.4 million in net proceeds from a recent public offering, ending the quarter with $513.0 million in cash, which is expected to fund operations into the second half of 2029 [4][11] Business Highlights - The Phase 2a clinical trial of RAP-219 met its primary endpoints with high statistical significance, showing 85.2% of patients achieving a ≥30% reduction in long episodes [5] - The company plans to initiate two Phase 3 pivotal trials of RAP-219 in focal onset seizures in Q3 2026 and expects topline results from the bipolar mania trial in the first half of 2027 [4][6] - An open-label long-term safety trial for patients from the Phase 2a trial is planned to begin by the end of 2025 [5] Financial Results - For Q3 2025, the company reported a net loss of $26.9 million, compared to a net loss of $17.5 million in the same period last year [11] - Research and Development (R&D) expenses increased to $22.3 million from $15.5 million year-over-year, driven by clinical development costs [11] - General and Administrative (G&A) expenses rose to $7.7 million from $6.1 million, reflecting business growth [11] Cash Position - The company ended Q3 2025 with $513.0 million in cash, cash equivalents, and short-term investments, a significant increase from $260.4 million as of June 30, 2025 [11] - The cash runway is expected to support operations and capital expenditures into the second half of 2029 [11]

Core Insights - Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders [17] - The company reported a net loss of $26.7 million for Q2 2025, an increase from $18.1 million in the same period last year [14] - The company ended the quarter with $260.4 million in cash and equivalents, expected to fund operations through the end of 2026 [5][14] Business Highlights - The Phase 2a trial of RAP-219 for drug-resistant focal onset seizures is fully enrolled, with topline results expected in September 2025 [5][8] - A Phase 2 trial of RAP-219 in bipolar mania has been initiated, with topline results anticipated in the first half of 2027 [9] - Plans for a Phase 2a trial in diabetic peripheral neuropathic pain are being finalized, with an update expected in 2025 [10] Financial Results - Research and Development (R&D) expenses for Q2 2025 were $22.7 million, up from $15.7 million in the prior year [14] - General and Administrative (G&A) expenses increased to $6.8 million from $5.1 million year-over-year [14] - The company reported a net loss per share of $0.75 for Q2 2025, compared to $1.70 for the same period in 2024 [24] Clinical Development Updates - The Phase 2a trial of RAP-219 is designed to assess its effect on long episodes (LEs) in patients, with a primary endpoint of achieving a ≥30% reduction in LEs [6] - The trial population shows a concordance of 92% between long episodes and electrographic seizures, with patients experiencing an average of 51 long episodes per 28 days [6] - The company expects to analyze the proportion of patients achieving a ≥50% reduction in clinical seizures as a key secondary endpoint [6] Corporate Updates - Rapport hosted its inaugural Investor and Analyst Day on June 2, 2025, featuring presentations from key executives and discussions with leading epilepsy experts [11] - The company is committed to a disciplined approach in advancing its pipeline and delivering transformative treatments for patients [2]

Summary of Rapport Therapeutics (RAPP) 2025 Conference Company Overview - **Company**: Rapport Therapeutics (RAPP) - **Industry**: Biotechnology, specifically in precision neuroscience and epilepsy treatment - **Key Personnel**: Abe Cisse (CEO), Choi Ignelzi (CFO) [1][2] Core Points and Arguments - **Vision**: Rapport aims to be a leading precision neuroscience company, focusing on receptor associated proteins to develop targeted therapies [4][5]. - **Lead Program**: RAP-two 19, an AMPA TARP gamma-eight modulator, targets specific brain areas to modulate AMPA receptors, aiming to reduce adverse effects (AEs) associated with traditional anti-seizure medications [5][6]. - **Clinical Trials**: - Currently conducting a Phase 2a proof of concept study for RAP-two 19 in focal epilepsy, fully enrolled with 30 patients, with data expected in September 2025 [7][8]. - Plans to explore RAP-two 19 in bipolar mania and peripheral neuropathic pain, with a long-acting injectable formulation also in development [8][9][10]. - **Differentiation**: RAP-two 19 is designed for once-daily dosing with a long half-life, aiming to minimize drug-drug interactions (DDIs) and improve patient adherence [12][14][15][16]. Important Data and Metrics - **Phase 1 Studies**: Completed four studies with 100 healthy volunteers, showing a favorable tolerability profile and high receptor occupancy (up to 85%) without significant sedation or motor impairment [23][24]. - **Efficacy Expectations**: The primary endpoint for the Phase 2a study is a 30% reduction in long episodes of seizures, with a target responder rate of at least 40% [38][39]. - **Safety Profile**: No serious adverse events (SAEs) reported; mild AEs observed were transient and resolved on their own [45][46]. Additional Insights - **Biomarker Utilization**: The study leverages an implantable RNS device to capture EEG activity, providing an objective measure of efficacy compared to traditional seizure diaries [28][30]. - **Regulatory Pathway**: The company plans to conduct two registrational trials for NDA submission, with the potential to start in 2026 [51][52]. - **Market Positioning**: The combination of efficacy, tolerability, and administration profile positions RAP-two 19 as a potentially best-in-class therapy for epilepsy [41][44]. Conclusion Rapport Therapeutics is advancing its lead program RAP-two 19 with a focus on precision neuroscience, aiming to address significant unmet needs in epilepsy treatment through innovative clinical trial designs and a differentiated safety profile. The upcoming data readout in September 2025 will be critical for the company's future development plans and market positioning.

Summary of Rapport Therapeutics Investor and Analyst Day Company Overview - **Company**: Rapport Therapeutics - **Event**: Inaugural Investor and Analyst Day - **Focus**: Lead candidate RAP-two 19 for epilepsy treatment Key Points and Arguments Industry and Product Focus - **Lead Candidate**: RAP-two 19, a TARP gamma eight AMPA modulator, aimed at treating focal onset seizures in epilepsy [3][19] - **Market Size**: Focal epilepsy affects approximately 1.8 million patients in the U.S., with 30-40% being drug-resistant [32] - **Pipeline**: Fully enabled pipeline including RAP-two 19 and two late-stage discovery programs targeting chronic pain and hearing disorders [19][27] Clinical Trials and Results - **Phase Two Trial**: Ongoing trial for RAP-two 19 in focal onset seizure patients, fully enrolled with results expected in September [21][26] - **Phase One Results**: Completed four Phase I studies with 100 healthy volunteers; RAP-two 19 was safe and well-tolerated [52][53] - **Receptor Occupancy**: Achieved target receptor occupancy of 50-70% at lower doses than predicted, indicating potential for effective treatment [56][58] Scientific Insights - **Mechanism of Action**: RAP-two 19 selectively modulates AMPA receptors in specific brain regions, potentially reducing side effects associated with traditional anti-seizure medications [38][39] - **Preclinical Efficacy**: Demonstrated significant efficacy in animal models with a favorable safety profile compared to existing treatments [44][46] Management and Strategy - **Management Team**: Comprised of experienced professionals in neuroscience and drug development, emphasizing a strategic approach to building the company [15][17] - **Vision**: To create a leading precision neuroscience company, addressing the limitations of conventional small molecules in treating neurological disorders [24][25] Additional Important Content - **Unmet Needs**: Despite numerous treatment options, the number of treatment-resistant epilepsy patients remains unchanged, highlighting the need for innovative therapies [92][93] - **Patient Population**: The trial population is representative of refractory focal epilepsy patients, enhancing the translatability of results to broader populations [87] - **Long-Acting Injectable**: Potential development of a long-acting injectable formulation for RAP-two 19, which could transform treatment for epilepsy patients [29][30] Conclusion Rapport Therapeutics is positioned to address significant unmet needs in the epilepsy treatment landscape with its innovative lead candidate RAP-two 19, backed by a robust clinical and scientific foundation. The company's strategic focus on precision neuroscience and the experienced management team further enhance its potential for success in the market.

Core Viewpoint - Rapport Therapeutics is advancing its Phase 2a trial of RAP-219 in refractory focal epilepsy, which is fully enrolled and expected to report topline results in September 2025, marking a significant milestone for the company and its precision neuroscience approach [3][4][10] Group 1: Clinical Trial Updates - The Phase 2a trial of RAP-219 is designed with input from leading epilepsy experts and utilizes intracranial electroencephalography (iEEG) data to assess the drug's potential effect on long episodes (LEs), a biomarker correlated with clinical seizures (CSs) [4] - Preliminary baseline characteristics of the first 14 enrolled patients indicate that the trial population is representative of historical registrational refractory focal epilepsy trials, with a median age of 37 years and a balanced sex distribution of 7 females and 7 males [5][6] - The company anticipates providing detailed analyses of primary and secondary endpoints, treatment-emergent adverse events (TEAEs), and a consolidated safety summary from Phase 1 trials when topline results are reported [9][12] Group 2: Financial and Operational Insights - As of March 31, 2025, Rapport reported $285.4 million in cash, cash equivalents, and short-term investments, which are expected to support operations through the end of 2026 [10] - The company has conducted four Phase 1 trials involving 100 healthy volunteers, reinforcing RAP-219's differentiated tolerability profile [9][10] Group 3: Future Catalysts - Upcoming milestones include the topline readout for RAP-219 in focal epilepsy in September 2025, initiation of a Phase 2a trial in bipolar mania in Q3 2025, and updates on the diabetic peripheral neuropathic pain program in the second half of 2025 [13]